Strides receives USFDA approval for Pregabalin Capsules
The Pregabalin capsules has a market size of ~US$248 mn per IQVIA
The Pregabalin capsules has a market size of ~US$248 mn per IQVIA
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The product has been in-licensed from Strides and will be commercialized by Amneal
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated